Kratom Research Institute

Policy · 2026-05-19

Philadelphia City Council Schedules Hearing on Bill That Would Effectively Ban Natural Kratom Leaf Citywide

Source: Super Speciosa / Protect Kratom

Why it matters

Philadelphia City Council is considering legislation that, while framed as consumer protection, would in practice ban all natural kratom sales by requiring FDA pharmaceutical drug approval — a standard impossible for botanical products to meet. The outcome could set a precedent for other major cities.

The big picture

Bill 260163, introduced by Councilmember Katherine Gilmore Richardson, would regulate intoxicating substances including kratom and hemp products. The bill includes consumer protections praised by regulation advocates — age-21 requirements, 2% 7-OH caps, lab testing, and labeling mandates. However, a provision requiring FDA Section 505 pharmaceutical approval creates what critics call a de facto prohibition, since no kratom product can obtain pharmaceutical drug approval under current regulatory frameworks.

Key findings

What they say

Kratom advocates from Protect Kratom characterized the bill as 'prohibition by another name,' arguing: 'Applying a pharmaceutical drug approval requirement to a natural botanical product is not consumer protection. It is prohibition by another name.'

Bottom line

Philadelphia's proposed kratom legislation contains real consumer protections, but a buried FDA pharmaceutical approval clause would effectively ban all natural kratom sales — making it one of the most sweeping city-level kratom restrictions in the country if passed.